JOHN CANALE: Open Payments
NPI 1578569620 · O FALLON, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,628 in 161 payments from 18 companies in 2025. Trend: 2023 $3,245 · 2024 $3,021 · 2025 $2,628
Food & beverage: $2,617Education: $12
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 16 | $378 |
| ABBVIE INC. | 34 | $340 |
| Otsuka America Pharmaceutical, Inc. | 16 | $254 |
| Axsome Therapeutics, Inc. | 13 | $216 |
| Alkermes, Inc. | 12 | $204 |
| E.R. Squibb & Sons, L.L.C. | 12 | $201 |
| Vanda Pharmaceuticals Inc. | 13 | $199 |
| Teva Pharmaceuticals USA, Inc. | 9 | $161 |
| Janssen Pharmaceuticals, Inc | 7 | $151 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $144 |
Products named: INGREZZA, VRAYLAR, REXULTI, Auvelity, COBENFY, FANAPT, ARISTADA, AUSTEDO XR.
Industry payments across MO — which companies pay providers there.
